Normal view MARC view ISBD view

Selegiline in Parkinson's disease.

Calne, D B

Selegiline in Parkinson's disease. [electronic resource] - BMJ (Clinical research ed.) Dec 1995 - 1583-4 p. digital

Publication Type: Editorial; Comment

ISSN: 0959-8138

Standard No.: 10.1136/bmj.311.7020.1583 doi

Subjects--Topical Terms:
Antiparkinson Agents--adverse effects
Clinical Trials as Topic
Drug Therapy, Combination
Humans
Levodopa--therapeutic use
Monoamine Oxidase Inhibitors--adverse effects
Neuroprotective Agents--adverse effects
Parkinson Disease--drug therapy
Selegiline--adverse effects
Treatment Failure
United Kingdom

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)